Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
BioViotica
Butyrolactone I
115
CHF
CHF 115.00
In stock
BVT-0448-C200200 µgCHF 115.00
BVT-0448-M0011 mgCHF 155.00
BVT-0448-M0055 mgCHF 505.00
| Product Details | |
|---|---|
| Product Type | Chemical |
| Properties | |
| Formula |
C24H24O7 |
| MW | 424.5 |
| CAS | 87414-49-1 |
| Source/Host Chemicals | Isolated from Aspergillus terreus. |
| Purity Chemicals | ≥98% (HPLC, NMR) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, methanol, ethanol or acetone. |
| Identity | Determined by 1H-NMR. |
| InChi Key | NGOLMNWQNHWEKU-UHFFFAOYSA-N |
| Smiles | COC(=O)[C@]1(CC2=CC=C(O)C(CC=C(C)C)=C2)OC(=O)C(O)=C1C1=CC=C(O)C=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light when in solution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at +4°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Cell permeable, potent and selective cyclin-dependent kinase CDK-1 (CDC2), -2 and -5 inhibitor [1-4, 9, 10].
- Apoptosis inducer [6, 7, 9].
- Antitumor agent [5, 9].
- Inhibits cell cycle progression at the G1/S and G2/M transitions [8].
- Shown to prevent the phosphorylation of retinoblastoma protein and H1 histone [2, 10].
- Important probe for understanding the cellular roles of CDKs [4].
- Inhibitor of α-glucosidases [12].
- Maturation inhibitor of sheep oocytes [11].
Product References
- Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase: M. Kitagawa, et al.; Oncogene 8, 2425 (1993)
- A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression: M. Kitagawa, et al.; Oncogene 9, 2549 (1994)
- Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract: T. Hosoi, et al.; J. Biochem. 117, 741 (1995)
- Chemical inhibitors of cyclin-dependent kinases: L. Meijer; Prog. Cell Cycle Res. 1, 351 (1995) (Review)
- Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines: K. Nishio, et al.; Anticancer Res. 16, 3387 (1996)
- Transcriptional activation of the cdc2 gene is associated with Fas- induced apoptosis of human hematopoietic cells: Y. Furukawa, et al.; J. Biol. Chem. 271, 28469 (1996)
- An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells: M. Wada, et al.; Anticancer Res. 18, 2559 (1998)
- Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines: M. Suzuki, et al.; Cancer Lett. 138, 121 (1999)
- Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis: H. Lin, et al.; J. Biol. Chem. 279, 29302 (2004)
- Regulation of mitotic function of Chk1 through phosphorylation at novel sites by cyclin-dependent kinase 1 (Cdk1): T. Shiromizu, et al.; Genes Cells 11, 477 (2006)
- Butyrolactone-I reversibly inhibits but does not improve the maturation and subsequent development of sheep oocytes in vitro: L. Lu, et al.; J. Animal Vet. Adv. 12, 17 (2013)
- Effect on α-glucosidase inhibition and antioxidant activities of butyrolactone derivatives from Aspergillus terreus MC751: R. Dewi, et al.; Med. Chem. Res. 23, 454 (2014)
Related Products
